Prostate Cancer, Nutrition, and Dietary Supplements (PDQ®): Complementary and alternative medicine - Patient Information [NCI] - Questions and Answers About Zyflamend
What is Zyflamend?Zyflamend is a dietary supplement that contains 10 different herbs. Zyflamend contains extracts of rosemary, turmeric, ginger, holy basil, green tea, hu zhang (Polygonum cuspidatum, a source of resveratrol), Chinese goldthread, barberry, oregano, and Baikal skullcap.The extracts found in Zyflamend have anti-inflammatory activity and possible anticancer benefits. There is limited evidence about how Zyflamend may act against tumor growth. Zyflamend has been shown to interfere with the activity of COX-1 and COX-2 enzymes, which are involved in the development of inflammation and possibly cancer. Zyflamend may also act against the NF-kappa B and lipoxygenase (LOX) families of proteins that stimulate tumor growth. How is Zyflamend administered or consumed?Zyflamend is taken as a dietary supplement in capsule form. Have any preclinical (laboratory or animal) studies been conducted using Zyflamend?Laboratory and animal research has recently been done to study the effects of
Prostate Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Get More Information From NCI
Get more information on prostate cancer treatment. How to contact the National Cancer Institute (NCI) via phone (1-800-4-Cancer), online, or mail. Plus, details on how to search the NCI web site, and how to order NCI publications.
Prostate Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - Get More Information From NCI
National Cancer Institute for more cancer information.
Prostate Cancer, Nutrition, and Dietary Supplements (PDQ®): Complementary and alternative medicine - Patient Information [NCI] - Questions to Ask Your Health Care Provider About CAM
When considering complementary and alternative therapies, patients should ask their health care provider the following questions: What side effects can be expected?What are the risks associated with this therapy?Do the known benefits outweigh the risks?What benefits can be expected from this therapy?Will the therapy interfere with conventional treatment?Is this therapy part of a clinical trial?If so, who is sponsoring the trial?Will the therapy be covered by health insurance?
Prostate Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - About This PDQ Summary
PURPOSE OF THIS SUMMARY This PDQ cancer information summary for health professionals provides comprehensive,peer-reviewed,evidence-based information about prostate cancer screening. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions. REVIEWERS AND UPDATES This ...
Prostate Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Recurrent Prostate Cancer Treatment
OverviewIn recurrent prostate cancer, the selection of further treatment depends on many factors, including:Previous treatment.Site of recurrence.Coexistent illnesses.Individual patient considerations. Definitive radiation therapy can be given to patients with disease that fails only locally following prostatectomy.[1,2,3,4] An occasional patient can be salvaged with prostatectomy after a local recurrence following definitive radiation therapy; however, only about 10% of patients treated initially with radiation therapy will have local relapse only. In these patients, prolonged disease control is often possible with hormonal therapy, with median cancer-specific survival of 6 years after local failure.Cryosurgical ablation of recurrence following radiation therapy is associated frequently with a high complication rate. This technique is still undergoing clinical evaluation.Hormonal therapy is used to manage most relapsing patients with disseminated
Genetics of Prostate Cancer (PDQ®): Genetics - Health Professional Information [NCI] - nci_ncicdr0000299612-nci-header
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Genetics of Prostate Cancer
Prostate Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - Evidence of Harms
Any potential benefits derived from screening asymptomatic men for prostate cancer need to be weighed against the harms of screening and diagnostic procedures,and treatments for prostate cancer.
Prostate Cancer Prevention (PDQ®): Prevention - Health Professional Information [NCI] - Significance
Incidence and Mortality Carcinoma of the prostate is the most common tumor in men in the United States,with 234,460 new cases and 27,350 deaths expected in 2006.[ 1 ] A wide range of estimates of the impact of the disease are notable. The disease is histologically evident in as many as 34% of men in their fifth decade and in up to 70% of men aged 80 years and older.[ 2,3 ] Prostate cancer ...
Genetics of Prostate Cancer (PDQ®): Genetics - Health Professional Information [NCI] - Genes With Potential Clinical Relevance in Prostate Cancer Risk
While genetic testing for prostate cancer is not yet standard clinical practice, research from selected cohorts has reported that prostate cancer risk is elevated in men with mutations in BRCA1, BRCA2, and on a smaller scale, in mismatch repair (MMR) genes. Since clinical genetic testing is available for these genes, information about risk of prostate cancer based on alterations in these genes is included in this section. In addition, mutations in HOXB13 were reported to account for a proportion of hereditary prostate cancer. Although clinical testing is not yet available for HOXB13 alterations, it is expected that this gene will have clinical relevance in the future and therefore is also included in this section. The genetic alterations described in this section require further study and are not to be used in routine clinical practice at